AstraZeneca offers its preclinical data capture platform to pharma sector
AstraZeneca and Tessella are to offer their Preclinical Data Integration and Capture Tool (PreDICT) platform for use across the wider pharmaceutical industry
Developed in partnership with data analytics company Tessella, AstraZeneca’s PreDICT platform is designed to capture and analyse preclinical pharmacokinetic (PK), pharmacodynamics (PD) and efficacy data.
The platform ensures data integrity and allows scientists to rapidly find, integrate and share in vivo data sets for the prediction of optimal doses and schedules in clinical trials, according to Tessella.
PreDICT has flexible study templates that capture in-depth experiment detail at all study stages, automated data processing and integration; a single, central repository and search tool to enable access to an organisation’s entire preclinical data capture, standardised and automated study analysis in a configurable calculation engine, output of combined data sets from multiple studies into Excel- and Spotfire-compatible formats to enable data visualization, according to the company.
AstraZeneca said it has seen significant benefits from using the platform, including assured data integrity for preclinical studies, rapid integration of PK and PD data, 30% time saving for modelers producing PK/PD models to understand and predict exposure-response relationships, reduction of modelling outsourcing costs by up to 20% and improvements in data quality and confidence in data.
Alan Bell, director of life sciences at Tessella, said: “Many drug discovery organisations have a culture where capture, storage and sharing of complex data sets is spreadsheet-based, which leads to many practical problems.
“These data sets are pivotal to the development of every new drug and compounding the challenges, the studies are generated and modelled by multiple scientific groups, making data and knowledge management and timely communication incredibly difficult.
“AstraZeneca has proactively addressed these issues through the development of PreDICT.”
Susan Galbraith, SVP of oncology IMED from AstraZeneca, said: “It’s incredibly important that the management of our data is handled in the most accurate and efficient way possible in order to facilitate understanding and to more accurately predict clinical outcomes.
“We’ve used PreDICT for over 150 projects and the data capture and analysis has involved the consideration of over three and a half million result data points. PreDICT helps us analyse and visualise data quickly so that we can use it to deliver meaningful clinical benefits.”